Armata Total Current Assets vs Total Current Liabilities Analysis

ARMP Stock

USD 3.26 0.50 18.12%

Armata Pharmaceuticals financial indicator trend analysis is way more than just evaluating Armata Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Armata Pharmaceuticals is a good investment. Please check the relationship between Armata Pharmaceuticals Total Current Assets and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Total Current Assets vs Total Current Liabilities

Total Current Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Armata Pharmaceuticals Total Current Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.

The correlation between Armata Pharmaceuticals' Total Current Assets and Total Current Liabilities is 0.67. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Armata Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Armata Pharmaceuticals' Total Current Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Armata Pharmaceuticals are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Current Assets i.e., Armata Pharmaceuticals' Total Current Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Total Current Liabilities

Total Current Liabilities is an item on Armata Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Armata Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Armata Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Armata Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.As of 05/10/2024, Enterprise Value is likely to grow to about 234.9 M, while Selling General Administrative is likely to drop slightly above 11.1 M.

Armata Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Net Debt	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.93	0.87	0.87	-0.39	0.97	0.05	0.22	0.62	0.99	0.62	0.96	0.89	0.5	-0.18	0.93	0.97	0.71	0.8	0.31	0.89	-0.27	0.83	-0.23	0.11	-0.23
Short Long Term Debt Total	0.93		0.8	0.78	-0.61	0.94	0.01	0.1	0.42	0.95	0.42	0.9	0.94	0.32	-0.18	0.96	0.94	0.47	0.71	0.17	0.99	0.04	0.88	-0.15	0.02	-0.15
Other Current Liab	0.87	0.8		0.9	-0.26	0.86	0.09	0.03	0.57	0.85	0.57	0.92	0.72	0.48	-0.18	0.78	0.85	0.66	0.85	0.2	0.77	-0.23	0.63	-0.32	0.2	-0.32
Total Current Liabilities	0.87	0.78	0.9		-0.14	0.86	0.08	0.2	0.47	0.86	0.47	0.89	0.65	0.64	-0.14	0.73	0.86	0.67	0.97	0.21	0.75	-0.35	0.66	-0.22	0.12	-0.22
Total Stockholder Equity	-0.39	-0.61	-0.26	-0.14		-0.34	0.33	-0.2	-0.29	-0.41	-0.29	-0.25	-0.76	0.37	-0.11	-0.7	-0.33	-0.06	-0.1	-0.16	-0.59	-0.69	-0.35	0.06	0.03	0.06
Property Plant And Equipment Net	0.97	0.94	0.86	0.86	-0.34		0.16	0.07	0.48	0.98	0.48	0.98	0.85	0.57	-0.27	0.89	1.0	0.63	0.79	0.15	0.93	-0.28	0.92	-0.13	0.02	-0.13
Retained Earnings	0.05	0.01	0.09	0.08	0.33	0.16		-0.44	-0.23	0.06	-0.23	0.19	-0.11	0.54	-0.97	-0.09	0.15	0.05	0.04	-0.37	0.05	-0.32	0.31	0.69	-0.61	0.69
Accounts Payable	0.22	0.1	0.03	0.2	-0.2	0.07	-0.44		0.3	0.2	0.3	0.03	0.24	-0.05	0.42	0.24	0.08	0.25	0.31	0.72	0.08	-0.13	-0.1	-0.36	0.37	-0.36
Cash	0.62	0.42	0.57	0.47	-0.29	0.48	-0.23	0.3		0.52	1.0	0.51	0.58	0.24	0.17	0.59	0.48	0.89	0.4	0.27	0.3	-0.24	0.26	-0.35	0.33	-0.35
Non Current Assets Total	0.99	0.95	0.85	0.86	-0.41	0.98	0.06	0.2	0.52		0.52	0.96	0.9	0.46	-0.19	0.93	0.97	0.61	0.79	0.33	0.93	-0.22	0.85	-0.24	0.11	-0.24
Cash And Short Term Investments	0.62	0.42	0.57	0.47	-0.29	0.48	-0.23	0.3	1.0	0.52		0.51	0.58	0.24	0.17	0.59	0.48	0.89	0.4	0.28	0.31	-0.24	0.27	-0.35	0.33	-0.35
Common Stock Shares Outstanding	0.96	0.9	0.92	0.89	-0.25	0.98	0.19	0.03	0.51	0.96	0.51		0.79	0.57	-0.29	0.84	0.98	0.65	0.81	0.17	0.88	-0.34	0.86	-0.2	0.09	-0.2
Non Current Liabilities Total	0.89	0.94	0.72	0.65	-0.76	0.85	-0.11	0.24	0.58	0.9	0.58	0.79		0.16	-0.08	0.99	0.84	0.52	0.58	0.3	0.91	0.13	0.76	-0.19	0.06	-0.19
Other Current Assets	0.5	0.32	0.48	0.64	0.37	0.57	0.54	-0.05	0.24	0.46	0.24	0.57	0.16		-0.5	0.24	0.58	0.63	0.66	-0.23	0.31	-0.72	0.55	0.36	-0.33	0.36
Other Stockholder Equity	-0.18	-0.18	-0.18	-0.14	-0.11	-0.27	-0.97	0.42	0.17	-0.19	0.17	-0.29	-0.08	-0.5		-0.09	-0.26	-0.06	-0.1	0.33	-0.22	0.18	-0.43	-0.7	0.67	-0.7
Total Liab	0.93	0.96	0.78	0.73	-0.7	0.89	-0.09	0.24	0.59	0.93	0.59	0.84	0.99	0.24	-0.09		0.88	0.57	0.66	0.3	0.93	0.06	0.78	-0.2	0.07	-0.2
Property Plant And Equipment Gross	0.97	0.94	0.85	0.86	-0.33	1.0	0.15	0.08	0.48	0.97	0.48	0.98	0.84	0.58	-0.26	0.88		0.63	0.79	0.15	0.92	-0.3	0.92	-0.14	0.03	-0.14
Total Current Assets	0.71	0.47	0.66	0.67	-0.06	0.63	0.05	0.25	0.89	0.61	0.89	0.65	0.52	0.63	-0.06	0.57	0.63		0.63	0.1	0.38	-0.51	0.44	-0.14	0.19	-0.14
Short Term Debt	0.8	0.71	0.85	0.97	-0.1	0.79	0.04	0.31	0.4	0.79	0.4	0.81	0.58	0.66	-0.1	0.66	0.79	0.63		0.22	0.69	-0.36	0.58	-0.2	0.11	-0.2
Intangible Assets	0.31	0.17	0.2	0.21	-0.16	0.15	-0.37	0.72	0.27	0.33	0.28	0.17	0.3	-0.23	0.33	0.3	0.15	0.1	0.22		0.15	-0.14	-0.09	-0.65	0.5	-0.65
Net Debt	0.89	0.99	0.77	0.75	-0.59	0.93	0.05	0.08	0.3	0.93	0.31	0.88	0.91	0.31	-0.22	0.93	0.92	0.38	0.69	0.15		0.06	0.89	-0.11	-0.02	-0.11
Non Currrent Assets Other	-0.27	0.04	-0.23	-0.35	-0.69	-0.28	-0.32	-0.13	-0.24	-0.22	-0.24	-0.34	0.13	-0.72	0.18	0.06	-0.3	-0.51	-0.36	-0.14	0.06		-0.19	0.08	-0.11	0.08
Net Receivables	0.83	0.88	0.63	0.66	-0.35	0.92	0.31	-0.1	0.26	0.85	0.27	0.86	0.76	0.55	-0.43	0.78	0.92	0.44	0.58	-0.09	0.89	-0.19		0.13	-0.22	0.13
Common Stock Total Equity	-0.23	-0.15	-0.32	-0.22	0.06	-0.13	0.69	-0.36	-0.35	-0.24	-0.35	-0.2	-0.19	0.36	-0.7	-0.2	-0.14	-0.14	-0.2	-0.65	-0.11	0.08	0.13		-0.9	1.0
Short Term Investments	0.11	0.02	0.2	0.12	0.03	0.02	-0.61	0.37	0.33	0.11	0.33	0.09	0.06	-0.33	0.67	0.07	0.03	0.19	0.11	0.5	-0.02	-0.11	-0.22	-0.9		-0.9
Common Stock	-0.23	-0.15	-0.32	-0.22	0.06	-0.13	0.69	-0.36	-0.35	-0.24	-0.35	-0.2	-0.19	0.36	-0.7	-0.2	-0.14	-0.14	-0.2	-0.65	-0.11	0.08	0.13	1.0	-0.9

Click cells to compare fundamentals

Armata Pharmaceuticals Account Relationship Matchups

Armata Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.5M	39.5M	69.8M	95.8M	110.0M	115.5M
Other Current Liab	3.0M	3.5M	2.2M	6.2M	5.4M	5.7M
Total Current Liabilities	4.9M	6.7M	4.8M	24.9M	16.5M	17.3M
Total Stockholder Equity	14.6M	18.9M	25.4M	36.1M	(32.1M)	(30.5M)
Property Plant And Equipment Net	4.2M	12.8M	38.1M	46.7M	57.3M	60.1M
Retained Earnings	(157.5M)	(179.7M)	(202.9M)	(239.8M)	(308.8M)	(324.3M)
Accounts Payable	547K	956K	1.1M	1.7M	1.6M	1.3M
Cash	6.0M	9.6M	10.3M	14.9M	13.5M	11.2M
Non Current Assets Total	18.8M	28.7M	54.8M	68.8M	90.8M	95.4M
Cash And Short Term Investments	6.0M	9.6M	10.3M	14.9M	13.5M	11.3M
Common Stock Shares Outstanding	7.8M	16.4M	24.1M	34.3M	36.1M	37.9M
Liabilities And Stockholders Equity	25.5M	39.5M	69.8M	95.8M	110.0M	115.5M
Non Current Liabilities Total	6.0M	14.0M	39.6M	34.9M	125.6M	131.8M
Other Current Assets	622K	1.2M	4.7M	10.3M	2.3M	2.3M
Other Stockholder Equity	172.0M	198.4M	228.0M	275.5M	276.4M	251.6M
Total Liab	10.9M	20.7M	44.4M	59.8M	142.0M	149.1M
Property Plant And Equipment Gross	4.2M	12.8M	48.3M	57.8M	69.1M	72.6M
Total Current Assets	6.7M	10.8M	15.0M	27.0M	19.2M	11.1M
Net Debt	(3.2M)	3.5M	27.7M	34.0M	106.8M	112.2M
Non Currrent Assets Other	836K	(2.1M)	(8.3M)	(9.6M)	2.5M	2.6M
Common Stock Total Equity	99K	187K	271K	361K	324.9K	308.7K
Common Stock	99K	187K	271K	361K	324.9K	308.7K
Capital Surpluse	172.0M	198.4M	228.0M	275.5M	247.9M	245.6M
Property Plant Equipment	4.2M	12.8M	2.2M	3.6M	4.2M	4.4M
Net Tangible Assets	11.1M	15.4M	11.7M	22.3M	25.7M	17.0M
Other Assets	(1K)	23.1M	13.2M	18.6M	21.4M	22.5M
Net Invested Capital	14.6M	19.6M	25.4M	36.1M	50.2M	25.5M
Net Working Capital	1.8M	4.1M	10.2M	2.2M	2.7M	3.5M

Pair Trading with Armata Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Armata Stock

0.68	RVMD	Revolution Medicines Financial Report 13th of May 2024	Pair Corr
0.58	ELYM	Eliem Therapeutics	Pair Corr
0.53	ACRV	Acrivon Therapeutics Financial Report 14th of May 2024	Pair Corr
0.49	PULM	Pulmatrix	Pair Corr

The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.

The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Armata Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Armata Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Armata Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Armata Pharmaceuticals Stock:

How To Invest In Armata

Details

Is Armata Stock a good investment?

Details

What is Armata Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Armata Stock analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Transaction History View history of all your transactions and understand their impact on performance
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Commodity Directory Find actively traded commodities issued by global exchanges

Is Armata Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Armata Pharmaceuticals. If investors know Armata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Armata Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.91)

Revenue Per Share

0.126

Quarterly Revenue Growth

0.454

Return On Assets

(0.26)

Return On Equity

(34.39)

The market value of Armata Pharmaceuticals is measured differently than its book value, which is the value of Armata that is recorded on the company's balance sheet. Investors also form their own opinion of Armata Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Armata Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Armata Pharmaceuticals' market value can be influenced by many factors that don't directly affect Armata Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Armata Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Armata Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Armata Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Armata Total Current Assets vs Total Current Liabilities Analysis

Total Current Assets vs Total Current Liabilities

Total Current Assets vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Total Current Assets

Total Current Liabilities

Armata Pharmaceuticals fundamental ratios Correlations

Armata Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Armata Pharmaceuticals fundamental ratios Accounts

Pair Trading with Armata Pharmaceuticals

Moving against Armata Stock

Complementary Tools for Armata Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Non Current Liabilities Total

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock	- 0.9	Short Term Investments
Short Term Investments	- 0.9	Common Stock Total Equity
Non Current Liabilities Total	- 0.76	Total Stockholder Equity
Non Currrent Assets Other	- 0.72	Other Current Assets
Common Stock	- 0.7	Other Stockholder Equity